CLGN CollPlant Biotechnologies Ltd

Nasdaq collplant.com


$ 1.98 $ 0.00 (-0.25 %)    

Friday, 14-Nov-2025 14:51:00 EST
QQQ $ 608.81 $ 0.46 (0.08 %)
DIA $ 471.98 $ -2.94 (-0.62 %)
SPY $ 672.02 $ -0.11 (-0.02 %)
TLT $ 88.93 $ -0.51 (-0.57 %)
GLD $ 375.88 $ -6.91 (-1.8 %)
$ 1.975
$ 1.93
$ 1.95 x 600
$ 2.00 x 100
-- - --
$ 1.31 - $ 4.98
5,154
na
22.62M
$ 0.53
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 d-boral-capital-maintains-buy-on-collplant-biotechnologies-maintains-12-price-target

D. Boral Capital analyst Jason Kolbert maintains CollPlant Biotechnologies (NASDAQ:CLGN) with a Buy and maintains $12 price ...

 collplant-reports-technion-study-results-showing-collink3d-provides-consistent-tunable-and-animal-free-alternative-to-matrigel

A head-to-head study by Israel's Technion found that CollPlant's rhCollagen-based bioink, Collink.3D, outperformed Matr...

 mayo-clinic-develops-first-fully-humanized-3d-bioprinted-skin-model-using-collplants-plant-derived-rhcollagen

The bioprinted skin model is designed to serve as an alternative to animal testing for preclinical research.According to a scie...

 collplant-biotechnologies-announces-results-from-non-clinical-program-evaluating-photocurable-dermal-filler-plans-to-advance-product-candidate-into-clinical-trials

CollPlant is now moving towards clinical trials and scaling and optimizing its manufacturing to ensure readiness for the upcomi...

 d-boral-capital-maintains-buy-on-collplant-biotechnologies-maintains-12-price-target

D. Boral Capital analyst Jason Kolbert maintains CollPlant Biotechnologies (NASDAQ:CLGN) with a Buy and maintains $12 price ...

 hc-wainwright--co-reiterates-buy-on-collplant-biotechnologies-maintains-11-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates CollPlant Biotechnologies (NASDAQ:CLGN) with a Buy and mai...

 d-boral-capital-maintains-buy-on-collplant-biotechnologies-maintains-12-price-target

D. Boral Capital analyst Jason Kolbert maintains CollPlant Biotechnologies (NASDAQ:CLGN) with a Buy and maintains $12 price ...

 collplant-biotechnologies-q2-adj-eps-023-misses-014-estimate-sales-179000k-miss-2544m-estimate

CollPlant Biotechnologies (NASDAQ:CLGN) reported quarterly losses of $(0.23) per share which missed the analyst consensus estim...

 collplant-taps-bowman-bagley-to-lead-north-american-push-for-skin-and-tissue-tech

CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and ...

 collplant-biotechnologies-expands-agreement-with-stemcell-technologies-broadening-use-of-collplants-rhcollagen-in-clinical-and-commercial-applications

CollPlant's proprietary rhCollagen to be used in clinical and commercial applicationsREHOVOT, Israel, June 9, 2025 /PRNewsw...

 collplant-secures-european-patent-for-rhcollagen-based-soft-tissue-fillers-and-regenerative-implants

- Further protection granted in key territory applying to the significant and growing aesthetic and reconstructive markets - 

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION